SynthesisDermatology online journal2026
Safety and efficacy of intralesional triamcinolone in the treatment of nail psoriasis: A systematic review and meta-analysis.
Synthesis in Dermatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nail psoriasis is a chronic and disfiguring manifestation of psoriasis that substantially affects quality of life. Intralesional triamcinolone acetonide (ILTAC) is commonly used for localized disease, yet its efficacy and safety remain incompletely established. This systematic review and meta-analysis aimed to evaluate the therapeutic effectiveness and safety of ILTAC in nail psoriasis and to summarize key clinical and methodological features of available studies. The review followed PRISMA guidelines and was registered in the PROSPERO database. Comprehensive searches of 5 electronic databases through September 2023 identified 6 eligible studies, including randomized trials and observational cohorts, that evaluated ILTAC using standardized outcome measures such as the Nail Psoriasis Severity Index. Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB2) tool for randomized trials and the MINORS tool for nonrandomized studies. Pooled analysis demonstrated that ILTAC significantly improved nail psoriasis, with an overall odds ratio of 2.35 (95% CI, 1.20-4.60) and negligible heterogeneity (I
Indexed as
Identifiers
42246338What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.